The analysis of the PROFILE 1014 study provides a new benchmark for overall survival (OS) in patients with ALK-rearranged NSCLC and highlights the benefit of crizotinib for prolonging survival in this patient population (10). Here, ALK is linked to non-small cell lung carcinoma.